Top-News

Roche Holding Aktie News

Aktie
WKN:  851311 ISIN:  CH0012032113 US-Symbol:  RHHBF Branche:  Pharmazeutika Land:  Schweiz
344,20 €
+0,60 €
+0,17%
07:30:09 Uhr
Depot/Watchlist
Marktkapitalisierung *
34,95 Mrd. €
Streubesitz
16,26%
KGV
25,93
Dividende
9,70 CHF
Dividendenrendite
3,00%
Index-Zuordnung
-

Roche Holding News

02.12.25 - GlobeNewswire
Roche receives FDA clearance with CLIA waiver and CE Mark for its first point-of-care test for diagnosing Bordetella infections, including whooping cough (pertussis)
The point-​of-care test delivers PCR-​accurate results in just 15 minutes, enabling healthcare providers to act quickly and prevent severe complications and onward transmission. ...
19.11.25 - GlobeNewswire
European Commission approves Roche’s Lunsumio subcutaneous for relapsed or refractory follicular lymphoma
Lunsumio provides high rates of deep and long-​lasting responses in third-​line and later follicular lymphoma, a disease that typically becomes harder to treat each time a patient ...
18.11.25 - Der Aktionär
Roche‑Anteile heben ab: Das beflügelt den Pharma‑Riesen
18.11.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s giredestrant becomes the first oral SERD to show superior invasive disease-free survival in early breast cancer
At interim analysis, giredestrant demonstrated a statistically significant and clinically meaningful benefit versus standard-​of-care endocrine monotherapy These unprecedented ...
10.11.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s fenebrutinib shows unprecedented positive Phase III results as the potential first and only BTK inhibitor in both relapsing and primary progressive multiple sclerosis
The first (FENhance 2) of two pivotal RMS studies met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses compared to teriflunomide In a pivotal ...
03.11.25 - GlobeNewswire
Roche to present new data from its broad and innovative haematology portfolio at ASH 2025
Findings further demonstrate the effectiveness of Roche’s approved medicines in advancing treatment standards for people with blood disorders Data from innovative pipeline ...
03.11.25 - GlobeNewswire
Positive phase III data for Roche’s Gazyva/Gazyvaro show significant reduction in disease activity for systemic lupus erythematosus
Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion ...
30.10.25 - GlobeNewswire
Roche purchases shares in tender offer for 89bio, Inc
Basel, 30 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Roche’s wholly owned subsidiary Bluefin Merger Subsidiary, Inc., has accepted for payment ...
29.10.25 - GlobeNewswire
Roche receives CE mark for novel automated high-throughput Elecsys Dengue Ag test to diagnose dengue
New dengue antigen test delivers high clinical sensitivity and specificity, as well as inclusivity for all four dengue virus serotypes, helps clinicians confidently distinguish dengue from ...
28.10.25 - GlobeNewswire
Positive phase III results for Roche’s Gazyva/Gazyvaro in children and young adults with idiopathic nephrotic syndrome
Gazyva/Gazyvaro versus mycophenolate mofetil shows significantly more children and young adults achieved sustained complete remission at week 52  If approved, ...
23.10.25 - GlobeNewswire
Changes to the Roche Enlarged Corporate Executive Committee
Basel, 23 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Nina Schwab-​Hautzinger (1975) has been appointed Head of Group Communications and a ...
23.10.25 - GlobeNewswire
[Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong sales growth momentum of 7% (CER) in the first nine months of 2025; full-year earnings outlook raised
Basel, 23 October 2025
23.10.25 - GlobeNewswire
[Ad-hoc-Mitteilung gemäss Art. 53] Roche setzt starkes Wachstum in den ersten neun Monaten 2025 fort: Verkäufe steigen um 7% (CER) – Gewinn­prognose für das Gesamtjahr erhöht
Basel, 23. Oktober 2025
20.10.25 - GlobeNewswire
Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment
Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo 1 IMvigor011 is the first global phase III study to read out ...
20.10.25 - GlobeNewswire
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
FDA approval based on superiority of Gazyva/Gazyvaro over standard therapy alone, as shown in phase II NOBILITY and phase III REGENCY data 1,2 Gazyva/Gazyvaro is the only ...
18.10.25 - GlobeNewswire
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1 -mutated populations, respectively, in a post-CDK inhibitor setting, ...
17.10.25 - GlobeNewswire
Roche presents new phase III pivotal data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss
Vamikibart is the first non-​steroid targeted therapy designed to address inflammation driving UME and may offer a potential new treatment option for patients Vision improvements ...
17.10.25 - GlobeNewswire
CHMP recommends EU approval of Roche’s Gazyva/Gazyvaro for lupus nephritis
Positive recommendation based on phase II NOBILITY and phase III REGENCY data showing Gazyva/Gazyvaro’s superiority over standard therapy alone 1,2 Gazyva/Gazyvaro is the ...
16.10.25 - GlobeNewswire
Roche presents major advances for its sequencing by expansion technology(1), including a new GUINNESS WORLD RECORD™, at the ASHG conference 2025
Significant progress in bulk RNA sequencing, methylation mapping, multiomics integration, and spatial analyses unlocks research previously out of reach for traditional short read ...
13.10.25 - GlobeNewswire
Roche data at ESMO 2025 showcase advances in science and cancer care across multiple tumour types
Basel, 13 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it will present more than 30 abstracts across more than 10 cancer types at the European ...

Newssuche

Videos

newspaper
02.12.25 +8,18%
Technical Trading: DAX Long dienstags
DAX Long Typ: Turbo Open End WKN: VK2CGA Hebel:11,30 Laufzeit: OpenEnd Einstieg: Market ... Mehr »